Denali Therapeutics Inc.
DNLI
$15.20
$0.3052.05%
| Weiss Ratings | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.46 | |||
| Price History | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.78% | |||
| 30-Day Total Return | -35.56% | |||
| 60-Day Total Return | -33.85% | |||
| 90-Day Total Return | -41.47% | |||
| Year to Date Total Return | -27.09% | |||
| 1-Year Total Return | -23.06% | |||
| 2-Year Total Return | -35.53% | |||
| 3-Year Total Return | -47.60% | |||
| 5-Year Total Return | 7.01% | |||
| 52-Week High % Change | -55.33% | |||
| 52-Week Low % Change | 6.28% | |||
| Price | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $33.33 | |||
| 52-Week Low Price | $14.01 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.16B | |||
| Enterprise Value | 1.02B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.58 | |||
| Earnings Per Share Growth | 136.56% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.75 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $15.20 | |||
| Enterprise Value/EBITDA (TTM) | -2.07 | |||
| Enterprise Value/EBIT | -2.04 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 170.09M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 866 8548 | |||
| Address | 161 Oyster Point Boulevard South San Francisco, CA 94080 | |||
| Website | www.denalitherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -24.82% | |||
| Return on Equity | -- | |||
| Income Statement | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -319.41M | |||
| EBITDA (TTM) | -495.23M | |||
| EBIT (TTM) | -501.88M | |||
| Net Income (TTM) | -422.77M | |||
| Net Income Avl. to Common (TTM) | -422.77M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 3.95% | |||
| EPS Diluted (TTM) | -2.58 | |||
| EPS Diluted Growth (Q YOY) | 21.93% | |||
| Balance Sheet | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 832.33M | |||
| Cash Per Share (Q) | $4.89 | |||
| Total Current Assets (Q) | 864.44M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.23B | |||
| Current Ratio (Q) | 8.458 | |||
| Book Value Per Share (Q) | $8.53 | |||
| Total Assets (Q) | 1.37B | |||
| Total Current Liabilities (Q) | 102.21M | |||
| Total Debt (Q) | 54.32M | |||
| Total Liabilities (Q) | 144.50M | |||
| Total Common Equity (Q) | 1.23B | |||
| Cash Flow | DNLI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -88.76M | |||
| Cash from Financing (TTM) | 484.30M | |||
| Net Change in Cash (TTM) | 47.85M | |||
| Levered Free Cash Flow (TTM) | -208.83M | |||
| Cash from Operations (TTM) | -347.69M | |||
